Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HER2-positive (a type that grows quickly but can be treated with targeted therapy).
- Your cancer has come back (recurrent) or spread to other parts of the body (metastatic) and cannot be surgically removed.
- You have not had any prior systemic cancer treatment for this stage of the disease (except possibly trastuzumab in early-stage treatment).
- Your overall health is good (ECOG score 0 or 1) and your organs work well, such as normal blood counts and heart function (LVEF ≥50% measured by echocardiogram).
- You are between 18 and 75 years old and willing to use effective birth control during the study if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
This study looks at how well the drug pyrotinib works in people with advanced breast cancer that has spread and tests positive for HER2. HER2 is a protein that can make cancer cells grow, and pyrotinib targets it. If you have this type of breast cancer, this study may show if the treatment helps you.
This study tests giving certain targeted drugs before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach helps reduce tumor size and improve outcomes.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.